Table 1.
Marker | Clear cell RCC | Papillary RCC Type 1 | Papillary RCC Type 2 | Chromophobe RCC | Oncocytoma | Xp11.2 translocation RCC |
---|---|---|---|---|---|---|
VHL mutation | + (~90%) | - | - | - | - | - |
cMET mutation | - | + | - | - | - | - |
TP53 mutations | - | - | - | + | - | - |
Other mutations | PBRM1 (~50%), BAP1 (~15%), SETD2 (~15%) | NRF2, CUL3 | FH | - | Mitochondrial complex I genes | translocations of Xp11.2 (TFE3) or 6p21 (TFEB) |
CK8 | +/- | + | + | +/- | + | ND |
CAIX | + | +/- | + | - | - | + |
CAM 5.2 | + | + | + | + | + | - |
CD10 | + | + | + | +/- | +/- | + |
CD15 | + | + | + | - | + | ND |
CK18 | + | + | + | + | + | ND |
EMA | + | + | + | + | + | - |
GST-alpha | + | - | - | - | - | ND |
PAX2 | + | + | +/- | - | + | +/- |
PAX8 | + | + | + | + | - | + |
RCC Ma | + | + | +/- | - | - | + |
VIM | + | + | + | - | - | + |
AMACR | - | + | + | - | - | + |
CD117 | - | - | - | + | + | ND |
CK7 | - | +/- | -/+ | +/- | - | +/- |
CK19 | - | - | - | - | - | +/- |
CK20 | - | - | - | - | - | - |
c-KIT | - | +/- | +/- | + | + | ND |
CLDN7/8 | - | - | - | + | + | ND |
E-cadherin | - | + | +/- | + | - | + |
EpCAM | - | - | -/+ | + | +/- | ND |
Ksp-cad | - | - | - | - | + | + |
PVALB | - | - | - | + | +/- | ND |
TFE3 | - | - | - | - | - | + |
SMA | - | - | - | - | + | ND |
Legend: AMACR α-methylacyl coenzyme A racemase, CAIX carbonic anhydrase IX, CK7 cytokeratin 7, CLDN7/8 claudin 7/8, EMA epithelial membrane antigen, GST-alpha glutathione S-transferase alpha, EpCAM epithelial cell adhesion molecule, Ksp-cad kidney-specific cadherin, PVALB parvalbumin, RCC Ma renal cell carcinoma marker, SMA smooth muscle action, TFE3 Transcription factor E3 - transcription factor binding to IGHM enhancer 3, PAX2/8 paired box gene 2/8, VIM vimentin, ND no reported data